Share on LinkedInShare on LinkedIn

ARTICLE · 06 NOVEMBER 2018

Sample Shaming : FDA's Open Letter On Access To Samples

A&O Shearman
A&O Shearman
Contributor

A&O Shearman

Introducing A&O Shearman Unparalleled global depth for a changing world. Today more than ever,...

View firm profile
Explore more from A&O Shearman

Senior associate Timothy Slattery (Washington, D.C.-Antitrust) has authored the article "Sample Shaming: FDA's Open Letter on Access to Samples Under REMS Programs Publically Calls Out Branded Drug Manufacturers to Aid Generic Entry" ...

United StatesAntitrust/Competition Law

Senior associate Timothy Slattery (Washington, D.C.-Antitrust) has authored the article "Sample Shaming: FDA's Open Letter on Access to Samples Under REMS Programs Publically Calls Out Branded Drug Manufacturers to Aid Generic Entry" in Antitrust Advisors, a publication of the American Health Lawyers Association Antitrust Practice Group. The article was published in September 2018.

Read Sample Shaming: FDA's Open Letter on Access to Samples Under REMS Programs Publically Calls Out Branded Drug Manufacturers to Aid Generic Entry

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from